Doctors have clamored for easy-to-use medications throughout the pandemic, but the new drug, molnupiravir, has had an uneasy reception because of its modest efficacy and potential safety risks. Some experts say another tool will be helpful as the omicron variant, which is resistant to other key treatments, surges. But others say they would be hesitant to use the drug.